Compare Amer Sports Inc (AS) vs Bristol-Myers Squibb Co (BMY) Price & Performance

Amer Sports (AS) trades at $34.80, up 2.75% today, with strong Q1 2026 earnings beating estimates and raised full-year guidance. Technicals show a bearish trend near key support at $33, while fundamentals reflect robust revenue growth of 32% year-over-year and a 58.23% gross margin. Analyst sentiment is overwhelmingly positive with 12 buy ratings and a $56 consensus target, indicating 61% upside potential from current levels.

The outlook remains favorable given earnings momentum and raised guidance, but risks include reliance on Arc'teryx brand sustainability and competitive pressures. Valuation metrics like a P/E of 43.49 suggest premium pricing, requiring continued execution to justify upside. Net positive cash flow and institutional support provide stability amid technical weakness.

Bristol Myers Squibb (BMY) trades at $57.58, down 0.62% on the day, with a bullish technical signal from moving averages. The company demonstrates strong profitability with a 70.46% gross margin and 15.01% net income margin, though it faces a patent cliff risk. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.58 surpassing the $1.42 estimate. Analyst consensus shows a mixed but leaning positive view with 46% buy ratings and a $60 price target.

BMY offers value with a reasonable P/E of 16.13 and attractive 4.3% dividend yield, supported by 36 years of uninterrupted payments. However, investors must weigh the patent expiration headwinds against the company's growth portfolio, which now represents 54.1% of revenues. The stock presents a balanced opportunity for income-focused investors with moderate growth potential amid ongoing business transformation.